Cellarity raises $123 million in series b funding to pioneer a new approach to drug discovery, treating disease at the level of the cell as opposed to a single molecular target

Cambridge, mass., feb. 25, 2021 /prnewswire/ -- cellarity, a life sciences company founded by flagship pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in series b financing. the round included contributions from funds...
FHTX Ratings Summary
FHTX Quant Ranking